OncoPharm

Foundations in #OncoPharm returns to discuss everyone's favorite antineoplastic, dexamethasone, which is also an anti-emetic, and an oncology pre-med among other things.

Another week, another 2 studies of checkpoint inhibitors in NSCLC to talk about.

IMpower 110: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346

Checkmate-153: https://ascopubs.org/doi/full/10.1200/JCO.20.00131

Updates from ESMO 2020 & more on:

Bladder Cancer (JAVELIN Bladder 100 & DANUBE)

Lung Cancer (ADAURA & CROWN)

Breast Cancer (ASCENT, IMPASSION 130/131, monarchE)

And the first major publication of drugging the "undrugable" KRAS

The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory.

TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720

We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.

After brief diatribes on PO azacitidine and COMBI-AD's 5-year non-OS analysis, we focus on BROCADE3 and the background on BRCA-mutated metastatic breast cancer treatment.

BROCADE3: https://doi.org/10.1016/S1470-2045(20)30447-2

Chemotherapy-induced alopecia is the next in our series on Foundational #OncoPharm topics.

Our Landmarks in #OncoPharm Series returns to discuss ATAC: Anastrozole or Tamoxifen Alone or in Combination for adjuvant breast cancer treatment.

VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity.

Link: https://doi.org/10.1056/nejmoa2012971

Lots of new options for B-cell malignancies of all ages!

We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate).

Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.